Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON38408
NL-OMON38408
Completed
Not Applicable

Phase I clinical trial to assess safety and immunogenicity of an MVA-based influenza H5 vaccine in healthy adults - Phase 1 study with an MVA-based influenza H5 vaccine

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites27 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsfluInfluenza10047438

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
flu
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
27
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
July 4, 2014
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •18\-35 years of age
  • •Female volunteers must acquire an acceptable form of contraception during the study period and to have a negative pregnancy test on the days of immunization.
  • •Refrain from blood donation during the study period
  • •Written informed consent
  • •Able and willing to comply with all study requirements

Exclusion Criteria

  • •Pregnancy or lactation
  • •Acute or chronic illness
  • •Known allergy to eggs, egg products or chicken protein
  • •Previous immunization with a recombinant MVA
  • •Previous immunization with an influenza A/H5N1 vaccine

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
A Phase I clinical trial to assess safety and immune response of Influenza vaccine of Serum Institute of India Limited in Adults.
CTRI/2011/09/002033Serum Institute of India Ltd Pune India40
Completed
Phase 1
Study to evaluate safety and possible adverse reactions, especially serious, with a vaccine for measles and rubella in healthy subjects.Measles and Rubella
RBR-9hckj4Bio-Manguinhos/Fiocruz/MS
Active, not recruiting
Not Applicable
Phase I and IIa trial to assess the safety, immunogenicity and protective efficacy against sporozoite challenge of the candidate malaria vaccine pfLSA-3 vaccine. - LSA3-trialP. falciparum infection (malaria)
EUCTR2006-001743-66-NLINSTITUT PASTEUR, Biomedical Parasitology Unit
Recruiting
Not Applicable
A Phase I trial to assess safety and immunogenicity of i.d. DNA priming and i.m. MVA boosting in healthy volunteers in MozambiqueHIV/AIDS
PACTR201106000304583Swedish Institute for Infectious Disease Control24
Recruiting
Phase 1
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9Influenza prophylaxisTherapeutic area: Diseases [C] - Virus Diseases [C02]
CTIS2022-500706-18-01Oslo University Hospital Hf30